3Kikkawa R, Koya D, Haneda M. Progression of diabetic nephropathy [J]. Am j Kidney Dis, 2003, 41 (3 Suppl 1) : S19 -21.
4Kanwar YS, Sun L, Xie P, et al. A glimpse of various pathogenetic mechanisms of diabetic nephropathy EJ]. Annu Rev Pathol, 2011, 28 (6) : 395 -423.
5Rosario RF, Prabhakar S. Lipids and diabetic nephropathy [ J ]. Curr Diab Rep, 2006, 6 (6): 455-462.
6Agarwal R. Effects of statins on renal function [ J ]. Am J Cardiol, 2006, 97 (5): 748-755.
7Kalaitzidis R, Bakris GL Effects of angiotensin II ceptor blockers on diabetic nephropathy [J]. J Hypertens Suppl, 2009, 27 (5): 15 - 21.
8Abel T, Feh6r J, Role of rosuvastatin in current lipid - lowering therapy [J]. Orv Hetil, 2010, 151 (35): 1424-1428.
9Laeourcire Y, Poirier L Valsartan is more effective than placebo in re- dueing the incidence of diabetes in people with impaired glucose toler- ance and cardiovascular disease or risk factors but has no effect on cardio- vascular outcomes [ J]. Evid Based Med, 2011, 16 (4) : 122 - 123.
10Abe H. Recent progress in understanding the molecular pathogenesis of diabetic nephropathy [J]. Rinsho Byori, 2011, 59 (2): 179-186.
